Since then, other SGLT2 inhibitors, Canagliflozin (Neal et al., 2017) and Dapagliflozin (Wiviott et al., 2019), have been found to have cardiovascular protection in patients with type 2 diabetes mellitus (Zelniker et al., 2019). Here, SLC5A2 is linked to diabetes mellitus.